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Background: Most Hodgkin lymphomas (HL) can be cured with current strategies. However, 
one-third of the cases do not respond or relapse and need salvage regimens. We report the results 
of a retrospective study using the gemcitabine and oxaliplatinum (GemOx) regimen.
Methods: Patients who relapsed or failed to achieve complete response were eligible and 
received GemOx salvage therapy. To avoid selection bias and thus to overcome the retrospective 
nature of the study, all treated patients were included from the pharmacy database.
Results: Between 2003–2013, 24 HL patients – relapsing (number [n]=12) or refractory 
(n=12) – were included, receiving a total of 26 induction treatments with GemOx. Mean previ-
ous regimens were 2.38 (42% relapsing after autologous transplantation). Median follow-up 
was 37 months, and 71% responded (38% of patients achieved complete response). The factors 
related to better progression-free survival were: B symptoms; response to GemOx; and con-
solidation with stem cell transplantation. Grades 1 and 2 neurological toxicity was present in 
17% of patients. Hematological toxicity was common, with grades 3 and 4 neutropenia (25%) 
and thrombocytopenia (34%) observed. Progression-free survival was better in patients con-
solidated with stem cell transplantation. The peripheral blood stem cell collection after GemOx 
was successful for all candidates.
Conclusion: 1) The GemOx regimen is effective in relapsed or refractory HL with manageable 
toxicity. 2) No mobilization failures were observed. 3) Consolidation after response is needed. 
4) Its efficacy and favorable toxicity profile might make multiple administrations possible in 
several recurrences in HL.
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Introduction
Hodgkin lymphoma (HL) represents 10%–15% of all types of lymphomas.1 At present, 
more than 70% of patients can be cured with the current strategies based on chemo-
therapy, with or without radiotherapy. However, one-third of the cases finally relapse 
and need salvage regimens that are usually consolidated with high-dose chemotherapy 
and autologous stem cell transplantation (ASCT).2
The patients that relapse after ASCT pose a great challenge as there is no stan-
dard strategy, although new drugs such as brentuximab vedotin have been approved 
in this setting.3 Furthermore, some cases have a pattern of relapses and remissions, 
which defines a chronic evolution. There are many salvage regimens (intensive non-
myeloablative regimens, such as mini-BEAM (carmustine, etoposide, cytarabine, 
melphalan), platinum-based regimens, ifosfamide-based and etoposide-based protocols, 
gemcitabine-based combinations, and new anti-CD30-based immunoconjugates), 
but there are no prospective randomized trials comparing one regimen with another. OncoTargets and Therapy 2014:7
Table 1 selected salvage regimens in relapsed or refractory hl
Regimen Patients ORR (CR) Grade 3–4 hematologic  
toxicity
Grade 3–4 nonhematologic 
toxicity
nonmyeloablative intensive regimens
  Mini-BeaM22 
  Dexa-BeaM17,23
55 
144
84% (51%) 
81% (27%)
86% 
100%23
61% 
49%
Platinum-based
  DhaP18 
  ashaP24 
  eshaP19
102 
56 
22
88% (21%) 
70% (34%) 
73% (41%)
48% 
100% 
59%
24% 
0% 
ns
ifosfamide-based
  Mine25 
  ice20,26 
  iVOx8
100 
65 
34
75% (35%) 
88% (26%) 
76% (32%)
92% 
72%26 
9%
16% 
ns 
ns
gemcitabine-based
  gVD21 
  igeV27
91 
91
70% (19%) 
81% (54%)
63% 
28%
8% 
5%
new drugs
  Bendamustine16 
  Brentuximab vedotin15
36 
102
53% (33%) 
73% (32%)
34% 
21%
14% 
17%
Abbreviations: Orr, overall response rate; cr, complete response; BeaM, carmustine, etoposide, cytarabine, melphalan; DhaP, cisplatin, cytarabine, dexamethasone; 
ASHAP, adriamycin, cisplatin, cytarabine, methylprednisolone; ESHAP, etoposide, cisplatin, cytarabine, methylprednisolone; NS, not significant; MINE, mesna, ifosfamide, 
mitoxantrone, etoposide; ice, ifosfamide, carboplatin, etoposide; iVOx, ifosfamide, etoposide, oxaliplatin; gVD, gemcitabine, vinorelbine, and pegylated liposomal doxorubicin; 
igeV, ifosfamide, gemcitabine, vinorelbine.
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These regimens obtain overall response rates (ORR) between 
70%–88% with complete response (CR) rates ranging from 
19%–54%, depending on the type of patients and disease 
(Table 1). However, most regimens are quite toxic and dif-
ficult to administer more than once to the same patient. For 
this reason, new drugs and combinations are needed to obtain 
both significant activity and a favorable toxicity profile, 
especially for patients experiencing multiple relapses. Ideally, 
these combinations should also not inhibit peripheral blood 
progenitor cell mobilization, since consolidation with ASCT 
is important in the first relapse.4
We previously reported the clinical activity of the gem-
citabine and oxaliplatinum (GemOx) regimen in diffuse large 
B-cell5 and mantle cell6 lymphoma with good results in the 
salvage setting. Combinations with gemcitabine have been 
tested in HL and are less toxic, and are better mobilizers, with 
better results noted in terms of progression-free survival (PFS) 
compared to intensive salvage regimens.7 In terms of efficacy 
and toxicity, the reported results are promising with the 
oxaliplatin-based regimen of combined ifosfamide, etoposide, 
and oxaliplatin (IVOx).8 Herein, we present our experience 
with the GemOx regimen in relapsed or refractory HL.
Materials and methods
Patients and study design
Between 2003–2012, 24 patients with HL were included in 
a retrospective study of salvage treatment with GemOx from 
the following centers in Spain: Son Espases Hospital, Palma 
de Mallorca; Son Llàtzer Hospital, Palma de Mallorca; Can 
Misses Hospital, Ibiza; and Mateu Orfila Hospital, Menorca. We 
obtained approval from the hematology research review board 
of Son Espases Hospital. We had the following inclusion crite-
ria: patients with a diagnosis with HL, which relapsed or failed 
to achieve CR after induction treatment; the provision of signed 
informed consent; and patients who received GemOx salvage 
therapy. The exclusion criteria were: patients with severe 
concomitant medical or psychiatric illnesses; HIV-positive; 
bilirubin levels .1.5 mg/dL; a cardiac ejection fraction ,50%; 
creatinine clearance ,30 mL/minute; a pumonary function test; 
and diffusing lung capacity ,50% of the predictive value. The 
pathologist in each center made the histological diagnosis. We 
obtained the patients from a pharmacy database to avoid selec-
tion bias, and we made sure to include all the patients with HL 
who had received the GemOx regimen in this 10-year period 
with an intention to treat. Primary and secondary endpoints 
were ORR and PFS, respectively.
A retrospective review of staging and response assess-
ment of every case was made to warrant uniform criteria. 
The disease stage was evaluated according to the Ann 
Arbor staging system, and patients were staged according 
to the standard procedures of physical examination, blood 
and serum assays, chest X-rays, and a computed tomography 
scan of the neck, chest, abdomen, and pelvis. Bone mar-
row aspirates and biopsies were obtained prior to therapy. OncoTargets and Therapy 2014:7
Table 2 characteristics of patients
Characteristics at diagnosis Number of 
patients (%)
Median age, years (range) 27 (14–76)
sex (male/female) (%) 50%/50%
ecOg Ps .2 2 (8%)
ann arbor stage iii–iV 13 (54%)
iPs .2 11 (49%)
B symptoms 12 (50%)
.1 extranodal site 6 (25%)
Bulky disease 6 (25%)
characteristics pre-gemOx
  Median previous lines (range) 2 (1–6)
  .1 previous line 17 (71%)
  Previous ascT 10 (42%)
Abbreviations: ecOg, eastern cooperative Oncology group; Ps, performance 
status; iPs, international Prognostic score; gemOx, gemcitabine and oxaliplatinum; 
ascT, autologous stem cell transplantation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2095
salvage therapy with gemOx in hodgkin lymphoma
Standard variables of the International Prognostic Score9 and 
other variables of known prognostic importance in this type of 
lymphoma were evaluated. CR was defined as the disappear-
ance of all clinical evidence of lymphoma for a minimum of 
4 weeks, with no persisting symptoms related to the disease. 
Partial response (PR) was defined as a decrease .50% in 
the sum of the products of the two longest diameters of all 
measurable lesions for at least 4 weeks, while immeasurable 
lesions had to have decreased by at least 50%. Lesions that 
increased in size or new lesions could not be considered as 
PR. Progressive disease was defined as any increase .25% 
in the sum of the diameter of any measurable lesions or the 
appearance of a new lesion. Patients who did not achieve PR 
or who had progressive disease within 1 month of therapy 
were considered refractory patients. Relapsed or refractory 
patients were confirmed with a biopsy.
Patients who did not achieve CR after the induction regi-
men, or who were relapsing, were given GemOx. This regi-
men consisted of gemcitabine 1,000 mg/m2 and oxaliplatin 
100 mg/m2 on day 1. If feasible, treatment was given every 
15 days and, if not, every 21 days. No use of prophylactic 
growth factors was contemplated. No dose reductions were 
planned relating to prior received therapy.
response, toxicity assessment,  
and follow-up criteria
We used the standard guidelines for evaluations:10 physical 
examination; complete blood counts; serum biochemistry; 
bone marrow aspiration or biopsy; and radiological stud-
ies, as mentioned previously. We used the World Health 
Organization criteria to assess the toxicity relating to the 
regimen. We always considered toxic mortality if it was 
related to the procedure.
statistical methods
PFS (time to progression/relapse) and overall survival (OS) 
(time to death) were measured from the date of GemOx onset, 
and were estimated according to the Kaplan–Meier method.11 
We performed the comparisons between those interest vari-
ables with the log–rank test.12 A comparison between categori-
cal variables was made with the chi-square of Fisher’s exact 
test, as appropriate. All reported P-values were two-sided, and 
statistical significance was defined at P,0.05.
Results
Patient characteristics
From 2003–2013, we included 24 patients with HL in 
this study. All patients had relapsing (number [n]=12) or 
refractory (n=8) disease, or less than a CR after induction 
(n=4) of therapy. Drugs were administered for compassionate 
use. The clinical characteristics of the patients at diagnosis 
and prior to GemOx are reflected in Table 2. The median age 
was 27 years (14–76 years), and 49% had an International 
Prognostic Score higher than 2. Patients received a median 
of two previous regimens (1–6), and 71% received more 
than one regimen before GemOx, with ten patients (42%) 
relapsing after a prior ASCT (seven just before GemOx with 
a median response duration of 7 months, and three receiving 
from 2–3 additional lines prior to GemOx, as shown in Table 
3). Table 3 shows the previous lines of therapy used before the 
GemOx salvage treatment. Most patients received GemOx 
using a 21-day interval (n=17), and only seven patients 
received GemOx with a 14-day interval.
response and outcome
The ORR was 71%: 38% of responses were CRs; and 33% 
were PRs. Patients relapsing after ASCT (n=10) also had good 
response rates: ORR of 90% with 50% CR. With a median 
follow-up for living patients of 37 months (3–98 months), 
the median OS and PFS were 26 months and 14 months, 
respectively. As of the last follow-up, nine patients (37%) are 
still alive, and 15 patients (62%) had already died – ten (42%) 
of these were due to disease progression, four (14%) due to 
complications from a subsequent allogeneic transplant (graft 
versus host disease, thrombotic thrombocytopenic purpura, 
and bleeding), and one (3%) due to pneumonia. Interestingly, 
a patient who relapsed after five prior lines of treatment 
obtained a CR with the GemOx regimen, relapsing once again 
31 months after this salvage treatment. This patient was given 
GemOx again and achieved a new CR that was maintained OncoTargets and Therapy 2014:7
Table 3 Previous treatment lines
Previous lines N Treatment
1 7 First: aBVD (n=6/7) 
aBVD + ascT (n=1/7)
2 8 First: aBVD 
second: eshaP (n=3/8) 
eshaP + ascT (n=4/8) 
DhaP (n=1/8)
3 6 First: aBVD 
second: aBVD (n=1/6) 
eshaP (n=1/6) 
MOPP (n=1/6) 
DhaP (n=2/6) 
BeacOPP (n=1/6) 
Third: iFe (n=1/6) 
eshaP (n=3/6) + ascT (n=1/6) 
rT (n=2/6) + ascT (n=1/5)
4 2 First: aBVD (n=1/2) 
chOP (n=1/2) 
second: DhaP + ascT (n=1/2) 
hypercVaD (n=1/2) 
Third: iFe (n=1/2) 
eshaP + ascT (n=1/2) 
Fourth: methotrexate + vincristine (n=1/2) 
aBVD (n=1/2)
6 1 First: aBVD 
second: MOPP 
Third: eshaP + ascT 
Fourth: vinblastine/procarbazine/
cyclophosphamide/prednisone 
Fifth: rT 
sixth: Mine
Abbreviations: n, total number;  aBVD, adriamycin, bleomycin, vinblastine, dacarbazine; 
n, sample number; ascT, autologous stem cell transplantation; eshaP, etoposide, 
cisplatin, cytarabine, methylprednisolone; DhaP, cisplatin, cytarabine, dexamethasone; 
MOPP, nitrogen mustard, vincristine, procarbazine, prednisone; BeacOPP, bleomycin, 
etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone; 
iFe,  ifosfamide,  etoposide;  rT,  radiotherapy;  hypercVaD,  cyclophosphamide, 
vincristine,  adriamycin,  dexamethasone;  Mine,  mesna,  ifosfamide,  mitoxantrone, 
etoposide; chOP, cyclophosphamide, vincristine, adriamycin, prednisone.
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for 17 months, followed by a third consecutive GemOx line 
with a PR that lasted 11 additional months.
The main prognostic factors for HL were assessed to 
view their impact on survival. Factors related with PFS were: 
B symptoms; response to GemOx; and consolidation with 
stem cell transplantation. Obtaining a CR after GemOx also 
meant a better OS (Table 4 and Figure 1).
safety
A median of four cycles (1–12) of GemOx was administered 
per patient, and progression for a total of 123 cycles was 
evaluated in the current study (n=24 patients, with one patient 
receiving GemOx in three consecutive progressions). Table 5 
shows the adverse events associated with GemOx. Neurologic 
toxicity was present in 17% of patients; all of them were grade 
1 or 2. Hematological toxicity was also common, including 
grade 3 or 4 neutropenia in 25% of patients, and grade 3 or 4 
thrombocytopenia in 33% of patients. Nausea and vomiting 
occurred in all the patients at grade 2 or lower. No differences 
in neurological or hematological toxicity were seen in the 
analysis of toxicity when comparing patients with only one 
previous line of treatment against those with more than one.
Peripheral blood stem cell collection and 
hematopoietic stem cell transplantation
This is a high-risk series, as ten patients (42%) had relapsed 
after a prior ASCT. Another four patients were ineligible due 
to advanced age or comorbidities. So, only ten patients were 
potential candidates for ASCT before GemOx. However, 
five remained refractory, and only five patients were finally 
considered candidates for ASCT. Peripheral blood stem cell 
collection after GemOx and granulocyte colony-stimulating 
factor was successful with all of them. All cases received 
BEAM as the conditioning regimen. The outcome in these 
cases was excellent, with median PFS and OS not reached 
after a median follow-up of 69 months (23–81). At the last 
follow-up, only one of these five patients (20%) had relapsed 
and died. Five patients receiving GemOx when relapsing 
after a prior ASCT were consolidated with nonmyeloablative 
allogeneic stem cell transplantation (three related and two 
unrelated). Three cases died due to severe posttransplant 
complications, and two are still alive and disease-free.
Discussion
Although this is a retrospective series, we included all HL 
patients treated with GemOx from the pharmacy databases in 
this 10-year period in an intention-to-treat analysis to avoid 
selection bias. Our results show an encouraging effect of 
GemOx on relapsed or refractory HL in a poor-risk popula-
tion, with 42% of patients relapsing after ASCT. GemOx also 
featured a manageable toxicity profile that made multiple 
administrations of the regimen possible. Even though limited 
patient numbers have been included in two other reports and 
mixed with patients treated with other regimens or types of 
lymphoma,13,14 the present manuscript is the first one that 
specifically investigates the GemOx regimen in HL.
In spite of the multiple chemotherapeutic regimes that 
have been tested in relapsed or refractory HL, no prospec-
tive randomized trial has ever assessed which is the best 
combination in terms of efficacy or toxicity. Most impor-
tant traditional salvage regimens in HL include intensive 
nonmyeloablative regimens such as: mini-BEAM; platinum-
based regimens; ifosfamide- and etoposide-based protocols; OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2097
salvage therapy with gemOx in hodgkin lymphoma
and gemcitabine-based combinations.4 Also, most of them 
must be administered on an inpatient basis. Recently, new 
drugs, such as bendamustine and a new antibody–drug conju-
gate targeting CD30 brentuximab vedotin, have demonstrated 
efficacy in relapsed/refractory HL.15,16
In terms of efficacy, all the traditional and new salvage 
protocols reach ORRs of between 70%–88% with CR rates 
(CRR) from 19%–54%, depending on the type of patients 
and disease included in each report (Table 1). Our results 
with GemOx (71% ORR and 38% CRR) are encouraging, 
as they have been obtained in a heavily pretreated series 
of HL (2.38 median prior regimens and 42% relapses after 
ASCT). These results compare favorably with most tradi-
tional salvage regimens, particularly when toxicity issues 
are considered (46% grade 3 or 4 hematologic toxicity as 
the only severe toxicity).8,17–21
Furthermore, the GemOx regimen is an easily manage-
able outpatient regimen. GemOx combines the efficacy 
Table 4 Prognostic factors related to Os and PFs
Factor N Median OS 
(months) (95% CI)
P-value Median PFS 
(months) (95% CI)
P-value
age at diagnosis 
    14–44 years 
$45 years
 
18 
6
 
28 (0–58) 
19 (13–25)
0.66  
31 (0–63) 
6 (0–16)
0.088
sex 
    Male 
Female
 
12 
12
 
19 (0–38) 
28 (7–49)
0.50  
31 (2–61) 
11 (4–19)
0.74
number of previous lines 
   1  
.1
 
7 
17
 
26 (na) 
16 (0–43)
0.40  
nr 
14 (2–27)
0.52
Duration response prior gemOx 
    0–12 months 
.12 months
 
21 
3
 
26 (12–40) 
28 (0–62)
0.85  
17 (3–32) 
14 (1–27)
0.89
status at gemOx 
    Pr or relapse 
refractory
 
15 
9
 
28 (10–46) 
19 (0–38)
0.34  
17 (0–40) 
9 (0–19)
0.56
ann arbor stage at diagnosis 
    i–ii 
iii–iV
 
11 
13
 
16 (0–37) 
34 (13–54)
0.56  
6 (2–10) 
nr
0.081
B symptoms at diagnosis 
    no 
Yes
 
12 
12
 
34 (0–70) 
16 (6–27)
0.10  
31 (na) 
6 (0–12)
0.024
Bulky disease at diagnosis 
    Yes 
no
 
6 
16
 
28 (23–33) 
16 (4–29)
0.78  
4 (0–15) 
17 (2–33)
0.77
iPs at diagnosis 
    0–2 
3–7
 
12 
11
 
99 (na) 
26 (12–039)
0.26  
31 (na) 
9 (2–16)
0.22
response to gemOx 
    cr 
Pr 
refractory
 
9 
8 
7
 
99 (na) 
26 (0–56) 
13 (3–23)
0.064  
nr 
17 (11–24) 
2 (0–5)
,0.001
response to gemOx 
    cr 
less than cr
 
9 
15
 
99 (na) 
19 (0–38)
0.043  
nr 
11 (0–23)
0.062
consolidation with scT 
    Yes 
no
 
10 
14
 
nr 
16 (7–26)
0.14  
nr 
6 (2–11)
,0.001
consolidation with type scT 
    allo-scT 
ascT 
no
 
5 
5 
14
 
6 (0–35) 
nr 
16 (7–26)
0.14  
nr 
nr 
6 (2–11)
0.001
Abbreviations: OS, overall survival; PFS, progression-free survival; N, number; CI, confidence interval; NA, not available; NR, not reached; GemOx, gemcitabine and 
oxaliplatinum; Pr, partial response; iPs, international Prognostic score; cr, complete response; scT, stem cell transplantation; allo-scT, allogeneic stem cell transplantation; 
ascT, autologous stem cell transplantation.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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of gemcitabine and platinum-based regimens with lower 
toxicity, due to the addition of the less toxic oxaliplatin, 
which is devoid of the renal and otic toxicity present with 
cisplatin. We previously reported our experience in both 
diffuse large B-cell and mantle cell lymphoma in heavily 
pretreated patients with a high ORR of 43% and 85%, 
and grade 3–4 hematological toxicity of 43% and 35%, 
respectively.5,6 In mantle cell lymphoma, such as in HL, we 
found that this low-toxicity profile allowed us to administer 
the treatment consecutively and several times in the same 
patient. The tolerance and response were good. This may 
be particularly important in HL where some patients become 
chronic with multiple relapses and responses. In this series, 
we present a case that was controlled with three consecutive 
administrations of GemOx for 5 years, achieving two CRs 
and one PR.
Since ASCT is important in consolidating response in 
relapsed or refractory HL, a salvage regimen should ideally 
not inhibit future peripheral blood stem cell mobilization. 
Adequate stem cell collection was more likely after 
gemcitabine-based protocols than after intensive conven-
tional regimens.7 In our patients, most cases were relapses 
after a prior ASCT, or they were not eligible for this procedure 
due to age or progression. However, all patients eligible for 
ASCT had an excellent outcome. In fact, the median PFS of 
patients consolidated with ASCT or allogeneic SCT was not 
reached, while in nonconsolidated patients it was 6 months 
(P,0.001). Similarly, the need for response consolidation 
has also been observed after current promising new salvage 
therapies for relapsed HL, such as brentuximab vedotin, with 
a median PFS of 5.6 months.15
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Figure 1 Prognostic factors influencing OS and progression-free survival.
Abbreviations: cr, complete response; gemOx, gemcitabine and oxaliplatinum; Pr, partial response; allo-scT, allogenic stem cell transplantation; ascT, autologous stem 
cell transplantation; scT, stem cell transplantation; Os, overall survival.
Table 5 Maximum toxicity
Toxicities Maximum WHO toxicity grade 
(number of patients and %)
1–2 3 4
neuropathy 4 (17%) 0 0
neutropenia 3 (12%) 4 (17%) 2 (8%)
anemia 7 (29%) 2 (8%) 2 (8%)
Thrombocytopenia 6 (25%) 4 (17%) 4 (17%)
Abbreviation: WhO, World health Organization.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Conclusion
In conclusion, in our series of relapsed or refractory HL 
with a high rate of relapses after ASCT, the GemOx regi-
men showed good activity with manageable toxicity, low 
mobilization failure rates, and excellent outcomes when con-
solidated with hematopoietic stem cell transplantation. When 
  frontline standard strategies fail, the GemOx regimen may be 
considered as another alternative for patients with relapsed 
or refractory HL, as in the case of new drugs, such as bren-
tuximab vedotin or bendamustine.
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